Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.59%
#2 Venom Venom +25.04%
#3 Decred Decred +10.82%
#4 DexNet DexNet +7.57%
#5 Status Status +6.45%
#6 Wibx Wibx +5.98%
#7 SkyAI SkyAI +5.16%
#8 Talus Network Talus Network +4.56%
#9 Audiera Audiera +4.30%
#10 Palladium Network Palladium Network +4.13%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Xcell Therapeutics, Inc. Xcell Therapeutics, Inc.

Xcell Therapeutics, Inc.

373110
Rank in Stocks #30808
Xcell Therapeutics Inc. engages in the development and production of drugs for... Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is based in Seoul, South Korea.
Share Price
$0.87888834
Market Cap
$15.20M
Change (1 day)
-4.44%
Change (1 year)
-54.84%
Country
KR
Trade Xcell Therapeutics, Inc. (373110)

Category

Healthcare
P/E ratio for Xcell Therapeutics, Inc. (373110)
P/E ratio as of 2026 TTM: 0
According to Xcell Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Xcell Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.